Cargando…
Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients
BACKGROUND: The aim of this study was to investigate the expression level of circulating microRNA-31(miRNA-31) in lung cancer patients and its clinical significance. MATERIAL/METHODS: Real-time fluorescent quantitative PCR was utilized to detect the circulating miRNA-31 expression levels in 300 lung...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362487/ https://www.ncbi.nlm.nih.gov/pubmed/25765717 http://dx.doi.org/10.12659/MSM.893213 |
_version_ | 1782361820799959040 |
---|---|
author | Yan, Hai-Jun Ma, Ji-Yong Wang, Li Gu, Wei |
author_facet | Yan, Hai-Jun Ma, Ji-Yong Wang, Li Gu, Wei |
author_sort | Yan, Hai-Jun |
collection | PubMed |
description | BACKGROUND: The aim of this study was to investigate the expression level of circulating microRNA-31(miRNA-31) in lung cancer patients and its clinical significance. MATERIAL/METHODS: Real-time fluorescent quantitative PCR was utilized to detect the circulating miRNA-31 expression levels in 300 lung cancer patients and 300 health control subjects. The ROC curve was drawn to evaluate the diagnostic value of the circulating miRNA-31 expression levels in lung cancer. The 300 lung cancer patients were divided into a miRNA-31 low-expression group and a miRNA-31 high-expression group. A survival curve was drawn according to the Kaplan-Meier method to evaluate the prognostic value of the circulating microRNA-31 expression levels for lung cancer. RESULTS: The circulating miRNA-31 expression levels in the lung cancer patients (l.88±0. 67) increased significantly (P<0.001) compared to the healthy controls (0.58±0. 44). The area under the ROC curve drawn according to the circulating miRNA-31 expression levels was 0.785 (95% CI=0.486–0.763). When the critical value was 1.27, the sensitivity and specificity for lung cancer diagnosis according to the circulating miRNA-31 expression levels were 0.769 and 0.745, respectively. The difference in the survival curve between the miRNA-31 low-expression group (123 cases) and high-expression group (177 cases) was statistically significant (P=0.004). Median survival period of the low-expression group (38.44 months) was longer than that of the high-expression group (25.23 months). CONCLUSIONS: miRNA-31 may be a molecular marker for the diagnostic and prognostic evaluation of primary lung cancer. |
format | Online Article Text |
id | pubmed-4362487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-43624872015-03-25 Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients Yan, Hai-Jun Ma, Ji-Yong Wang, Li Gu, Wei Med Sci Monit Clinical Research BACKGROUND: The aim of this study was to investigate the expression level of circulating microRNA-31(miRNA-31) in lung cancer patients and its clinical significance. MATERIAL/METHODS: Real-time fluorescent quantitative PCR was utilized to detect the circulating miRNA-31 expression levels in 300 lung cancer patients and 300 health control subjects. The ROC curve was drawn to evaluate the diagnostic value of the circulating miRNA-31 expression levels in lung cancer. The 300 lung cancer patients were divided into a miRNA-31 low-expression group and a miRNA-31 high-expression group. A survival curve was drawn according to the Kaplan-Meier method to evaluate the prognostic value of the circulating microRNA-31 expression levels for lung cancer. RESULTS: The circulating miRNA-31 expression levels in the lung cancer patients (l.88±0. 67) increased significantly (P<0.001) compared to the healthy controls (0.58±0. 44). The area under the ROC curve drawn according to the circulating miRNA-31 expression levels was 0.785 (95% CI=0.486–0.763). When the critical value was 1.27, the sensitivity and specificity for lung cancer diagnosis according to the circulating miRNA-31 expression levels were 0.769 and 0.745, respectively. The difference in the survival curve between the miRNA-31 low-expression group (123 cases) and high-expression group (177 cases) was statistically significant (P=0.004). Median survival period of the low-expression group (38.44 months) was longer than that of the high-expression group (25.23 months). CONCLUSIONS: miRNA-31 may be a molecular marker for the diagnostic and prognostic evaluation of primary lung cancer. International Scientific Literature, Inc. 2015-03-09 /pmc/articles/PMC4362487/ /pubmed/25765717 http://dx.doi.org/10.12659/MSM.893213 Text en © Med Sci Monit, 2015 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License |
spellingShingle | Clinical Research Yan, Hai-Jun Ma, Ji-Yong Wang, Li Gu, Wei Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients |
title | Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients |
title_full | Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients |
title_fullStr | Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients |
title_full_unstemmed | Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients |
title_short | Expression and Significance of Circulating MicroRNA-31 in Lung Cancer Patients |
title_sort | expression and significance of circulating microrna-31 in lung cancer patients |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362487/ https://www.ncbi.nlm.nih.gov/pubmed/25765717 http://dx.doi.org/10.12659/MSM.893213 |
work_keys_str_mv | AT yanhaijun expressionandsignificanceofcirculatingmicrorna31inlungcancerpatients AT majiyong expressionandsignificanceofcirculatingmicrorna31inlungcancerpatients AT wangli expressionandsignificanceofcirculatingmicrorna31inlungcancerpatients AT guwei expressionandsignificanceofcirculatingmicrorna31inlungcancerpatients |